Product Description
The BioDeviceLab Human Intestinal Fatty Acid–Binding Protein (I-FABP) ELISA Kit is a high-performance enzyme-linked immunosorbent assay developed for the quantitative determination of I-FABP in biological samples. I-FABP is a small cytosolic protein highly expressed in mature enterocytes of the small intestine and is rapidly released into circulation upon epithelial cell damage.
Because of its tissue specificity and short half-life, I-FABP is widely used as a sensitive biomarker of acute intestinal epithelial injury, ischemia, inflammation, and barrier disruption. In gut-on-chip platforms, I-FABP provides a direct and quantitative readout of enterocyte damage in response to microbial challenge, hypoxia, inflammatory stimuli, drug exposure, or mechanical stress. This assay combines high analytical sensitivity, strong specificity, and robust reproducibility, making it suitable for both routine laboratory research and advanced biodevice validation workflows.
Intended Use
This kit is intended for the quantitative determination of human I-FABP in:
• Serum
• Plasma
• Urine
• Cell culture supernatants
Applications include gut-on-chip epithelial injury assessment, intestinal ischemia and inflammation studies, microbiome-induced damage modeling, drug toxicity screening, and biodevice calibration and benchmarking.
Assay Principle
This assay employs a sandwich ELISA format:
• I-FABP present in the sample binds to capture antibodies immobilized on a 96-well microplate.
• A biotinylated detection antibody specific to I-FABP binds to the captured protein.
• An enzyme conjugate is added, followed by chromogenic substrate (TMB).
• The enzymatic reaction generates a colorimetric signal measured at 450 nm.
• Absorbance is directly proportional to the I-FABP concentration in the sample.
Calibration Curve
• A calibration curve is generated using recombinant human I-FABP standards with known concentrations.
• Mean absorbance values are plotted against I-FABP concentration on a semi-logarithmic scale.
• A four-parameter logistic (4PL) regression model is recommended for curve fitting.
• Sample concentrations are calculated by interpolation from the standard curve.
Analytical Performance
Dynamic detection range: 0.05 – 20 ng/mL
Limit of detection (LOD): ≤ 0.02 ng/mL
Intra-assay CV: < 9%
Inter-assay CV: < 10%
Selectivity & Specificity
The assay demonstrates high specificity for I-FABP with minimal cross-reactivity to other fatty acid–binding proteins (L-FABP, H-FABP) or unrelated epithelial proteins (< 1%).
Kit Components
Each kit contains sufficient reagents for up to 96 determinations:
• Antibody-coated 96-well microplate
• Recombinant human I-FABP standards
• Biotinylated detection antibody
• Enzyme conjugate
• Assay buffer
• Wash buffer (10×)
• TMB substrate
• Stop solution
• Detailed assay protocol
Required Materials (Not Provided)
• Microplate reader capable of measuring absorbance at 450 nm
• Adjustable micropipettes and disposable tips
• Plate washer or manual washing equipment
• Plate shaker (recommended)
• Deionized or distilled water
Sample Collection & Handling
• Collect samples using standard laboratory procedures.
• Avoid repeated freeze–thaw cycles.
• Samples exceeding the highest standard should be diluted using assay buffer.
• Hemolyzed or contaminated samples may affect assay accuracy.
Quality Control
• Standards and controls should be included in each assay run.
• Duplicate measurements are recommended.
• Acceptance criteria should be established according to experimental requirements.
BioDeviceLab applies quality-controlled reagent preparation and batch-to-batch consistency practices to support reproducibility and scalability for biodevice development.
Storage & Stability
• Store all components at 2–8 °C.
• Do not freeze reagents unless explicitly stated.
• Unopened kits are stable until the stated expiration date.
• Opened reagents should be handled according to protocol recommendations.
Limitations
• For research use only.
• Not intended for diagnostic or therapeutic procedures.
• Results should be interpreted within the context of experimental design and intestinal injury model.
Applications
• Gut epithelial injury validation
• Intestinal ischemia and inflammation research
• Microbiome-induced epithelial damage modeling
• Drug toxicity and safety screening
• Biodevice calibration and benchmarking
